
KNSA Stock Forecast & Price Target
KNSA Analyst Ratings
Bulls say
Kiniksa Pharmaceuticals International PLC demonstrates a positive outlook due to its expanding prescriber base for Arcalyst, which grew from approximately 3,825 in Q3 to over 4,150 unique prescribers in Q4, indicating increasing acceptance among healthcare providers. The company's strong cash position of $414.1 million as of the end of Q4 2025, coupled with projected product sales revenue for Arcalyst reaching $900 million to $920 million in FY2026—reflecting about 34% year-over-year growth—further supports its financial health and pipeline development capabilities. Additionally, the anticipated launch of KPL-387, expected to enhance treatment efficacy and patient outcomes, presents further potential for revenue enhancement as awareness and treatment rates improve.
Bears say
Kiniksa Pharmaceuticals's stock faces a negative outlook primarily due to underwhelming clinical study results, including a modest average 4-point decrease in the NRS for symptomatic RP patients, which raises concerns about the efficacy of its key product candidates. Additionally, high turnover in critical regulatory positions such as CEO and CMO poses risks to investor confidence and stability within the company, potentially impacting share performance. The competitive landscape and regulatory risks associated with premium pricing for biologics in rare diseases further complicate the company's valuation and long-term profitability.
This aggregate rating is based on analysts' research of Kiniksa Pharmaceuticals Ltd and is not a guaranteed prediction by Public.com or investment advice.
KNSA Analyst Forecast & Price Prediction
Start investing in KNSA
Order type
Buy in
Order amount
Est. shares
0 shares